

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/583.683 Filing Date TRANSMITTAL June 19, 2006 📑 First Named Inventor **FORM** William J. Watkins Art Unit Unknown **Examiner Name** Unknown ed for all correspondence after initial filing) Attorney Docket Number 01692.315US2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify **Terminal Disclaimer** Extension of Time Request below): Form 1449 (6 pgs.); Copies of 84 cited Request for Refund **Express Abandonment Request** references; Return Postcard CD, Number of CD(s) \_\_\_\_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name VIKSNINS HARRIS & PADYS PLLP

Printed name	Robert J. Harris				
Date	November, 2006	Reg. No.	37,346		
	CERTIFICATE	OF TRANSMISSION/MA	ILING		
I hereby certify t sufficient postag the date shown	e as first class mail in an envelope address	ransmitted to the USPTO or deposed to: Commissioner for Patents, I	sited with the United States Postal Service with P.O. Box 1450, Alexandria, VA 22313-1450 on		
Signature					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Signature

Printed name

Typed or printed name

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

William J. Watkins

Examiner:

Unknown

Serial No.:

10/583,683 June 19, 2006

Group Art Unit: Docket:

Unknown 01692.315US2

PHOSPHONATE SUBSTITUTED KINASE INHIBITORS

## INFORMATION DISCLOSURE STATEMENT

immissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication. Applicant also encloses a copy of the corresponding International Search Report for your convenience.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered if required. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, William J. Watkins By his Representatives, Viksnins Harris & Padys PLLP P.O. Box 111098 St. Paul, MN 55111 952 876-4092

Date //-/-06

Robert J. Harris Reg. No. 37,346

CERTIFICATION OF HAND DELIVERY: The undersigned certifies that this correspondence is being hand delivered to the United States Patent Office in an package addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this \_\_\_\_\_ day of November 2006.

449B/PTO	PTO and/or	1449A/F	Substitute for form
OSURE	DISCL	ION	INFORMAT
ICAN <sup>1</sup>	Y APP	NT B	STATEME

many sheets as necessary)

Complete if Known	<del></del>	
Application Number	10/583,683	
Filing Date	June 19, 2006	
First Named Inventor	William J. Watkins	
Group Art Unit	Unknown	
Examiner Name	Unknown	

$\sim$	4	$\sim$	$\sim$	^			S2
II B	7	hu		ं द '	רי ו	1 1	~ /
ĸ		$\mathbf{U}$	_			u	

	US PATENT DOCUMENTS			
Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document	
	US 5,413,996	05-09-1995	Bodor, Nicholas S.	
	US 5,670,497	09-23-1997	Bold, Guido et al.	
	US 5,750,493	05-12-1998	Schinazi, Raymond F. et al.	
	US 5,874,577	02-23-1999	Chen, Wei et al.	
	US 5,914,332	06-22-1999	Chen, Xiaoqi et al.	
	US 6,072,053	06-06-2000	Vince, Robert et al.	
	US 6,312,662	11-06-2001	Robinson, Edward D. et al.	
	US 5,750,343	05-12-1998	Maag, Hans et al.	
	US 6,767,900	07-27-2004	Ubasawa, Masaru et al.	
	US 2001-031773	10-18-2001	Camden, James Berger	
	US-2003-0109498	06-12-2003	Yuasa, Satoshi et al.	

	FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)		
	EP 0 267 050	05-11-1988			
	EP 0 441 192	01-25-1991			
	EP 0 465 297	01-08-1992			
=	EP 0 531 597	03-17-1993			
	EP 0 632 048	01-04-1995			
	EP 0 786 455	07-30-1997			
	EP 0 852 233	07-08-1998			
	EP 0 919 562	06-02-1999			
	EP 1 295 879	03-26-2003			
	WO 88/06158	08-25-1988			
	WO 91/19721	12-26-1991			
	WO 92/00988	01-23-1992			
	WO 92/18520	10-29-1992			
	WO 93/12123	06-24-1993			
	WO 93/24510	12-09-1993			
	WO 96/14314	05-17-1996			
	WO 96/40156	12-19-1996			
	WO 98/04569	02-05-1998			
	WO 98/11906	03-26-1998			
	WO 99/62921	12-09-1999			
	WO 00/04033	01-27-2000			
	WO 01/13957	03-01-2001			

Substitute for form 1449A/PTO and/or 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/583,683	
(Use as many sheets as necessary)	Filing Date	June 19, 2006	
	First Named Inventor	William J. Watkins	
	Group Art Unit	Unknown	
	Examiner Name	Unknown	
Sheet 2 of 6	01692.315US2		

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	WO 01/17982	03-15-2001	
	WO 01/19320	03-22-2001	
	WO 01/46204	06-28-2001	
	WO 01/64693	09-07-2001	
	WO 01/96329	12-20-2001	
	WO 02/03997	01-17-2002	
	WO 02/06292	01-24-2002	
	WO 02/08241	01-31-2002	
	WO 02/14344	02-21-2002	
	WO 02/057425	07-25-2002	
-	WO 02/100415	12-19-2002	
	WO 03/028737	04-10-2003	
	WO 03/050129	06-19-2003	
	WO 03/059255	07-24-2003	
	WO 03/064383	08-07-2003	
	WO 03/066005	08-14-2003	
	WO 03/080078	10-02-2003	
	WO 03/090690	11-06-2003	
<u> </u>	WO 2004/096234	11-11-2004	
	WO 2005/011709	02-10-2005	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner	Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source
Initials*	(book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	ABDEL-MEGUID, SHERIN S. et al., Inhibition of Human Immunodeficiency Virus-1 Protease
	by a C <sub>2</sub> -Symmetric Phosphinate. Synthesis and Crystallographic Analysis, <i>Biochemistry</i> , 1993,
	1543-1572, Vol. 32, No. 31.
	ALLEN, LEE F. et al., CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK
	(MAPKK), Seminars in Oncology, October 2003, pp. 105-116, Vol. 30, No. 5, Elsevier Inc.
	BANTIA, SHANTA et al., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—
	a novel potent and orally active immunosuppressive agent, International
	Immunopharmacology, 2001, pp. 1199-1210, Elsevier Science B.V.
	BEAUCHAMP, LILIA M., et al., Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-
	d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine
	Nucleoside Phosphorylase, Journal of Medicinal Chemistry, 1996, pp. 949-956, American
	Chemical Society.
	BOHANI D. W. et al., A-420983: a potent, orally active inhibitor of lck with efficacy in a model of
	transplant rejection, Bioorganic & Medicinal Chemistry Letters, 2004, Vol. 14.

Substitute for form 1449A/PTO and/or 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/583,683	
(Use as many sheets as necessary)	Filing Date	June 19, 2006	
	First Named Inventor	William J. Watkins	
	Group Art Unit	Unknown	
	Examiner Name	Unknown	
Sheet 3 of 6	01692.315US2		

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
	BZOWSKA, AGNIESZKA <i>et al.</i> , Purine nucleoside phosphorylases: properties, functions, and clinical aspects, <i>Pharmacology &amp; Therapeutics</i> , 2000, pp. 349-425, Vol. 88, Elsevier Science
	Inc. CHAPMAN, H. et al., Practical Synthesis, Separation, and Stereochemical Assignment of the
	PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, Vol. 20, Nos. 4-7, Marcel Dekker, Inc.
	CLARK, JEREMY L. et al.,
	Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection.
	CONKLYN, MARYROSE et al., The JAK3 inhibitor CP-690550 selectively reduces NK and
	CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing, Journal of
	Leukocyte Biology, December 2004, pp. 1-8, Vol. 76, The Society for Leukocyte Biology.
	DE CLEREQ, E., Highlights in the Development of New Antiviral Agents, <i>Mini Reviews in Medicinal Chemistry</i> , 2002, 163-175, Vol. 2, No. 2., Bentham Science Publishers, Ltd.
	DE CLERCQ, ERIK, New Developments in Anti-HIV Chemotherapy, Current Medicinal Chemistry, 2001, 1543-1572, Vol. 8, No. 13, Bentham Science Publishers Ltd.
	DVORAKOVA, HANA et al., Synthesis of 2'-Aminomethyl Derivatives of N-(2-
	(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents, <i>J. Med. Chem.</i> , 1996, 3263-3268. Vol. 38, No. 17.
	EVANS, GARY B., Exploring Structure Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase, <i>J. Med. Chem.</i> , 2003, 3412-3423, Vol. 46, No. 15, American Chemical Society.
	GUMINA, GIUSEPPE et al., Advances in antiviral agents for hepatitis B virus, Antiviral Chemistry & Chemotherapy, 2001, 93-112, Vol. 12, Suppl. 1, International Medical Press.
	GOBEC, S. et al., Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall, <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, Vol. 14.
	HEGEDUS, LOUIS S. et al., Synthesis of 4'-Methyl and 4'-cyano Carbocyclic 2',3'-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones, <i>J. Org. Chem.</i> , 2004, 8492-8495, Vol. 69, No. 24, American Chemical Society.
	HERCZEGH P., et al., Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials, J. Med. Chem., 2002, Vol. 45.
	HIRABAYASHI, HIDEKI et al., Bone-Specific Drug Delivery Systems, Clinical Pharacokinetics, 2003, 1319-1330, Vol. 42, No. 15.
	HOLY A. et al., Synthesis, Cllect. Czech. Chem. Commun., 1989, Vol. 54, pages 2190-2210.
-	JAIN, JUGNU et al., Characterization of Pharmacological Efficacy of VX-148, a New, Potent
	Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor, Journal of
	Pharmacology and Experimental Therapeutics, 2002, 1272-1277, Vol. 302, No. 3, The
	American Society for Pharmacology and Experimental Therapeutics.
	KARPENKO, INNA L. et al., Synthesis and Antitherpetic Activity of Acyclovir Phosphonates, NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 2003, 319-328, Vol 22, No. 3, Marcel
	Dekker, Inc.

EXAMINER	DATE CONSIDERED
----------	-----------------

.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 4 of 6	01692.315US2	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
- IIIIIII	KATO, KEISUKE et al., Stereoselective synthesis of 4' - alphaalkyclcarbovir derivatives
	based on an asymmetric synthesis or chemo-enzymatic procedure, Chemical &
	Pharmaceutical Bulletin, 1999, 1256-1264, Vol. 49, No. 9, Pharmaceutical Society of Japan.
	KATO, KEISUKE et al., Enantio- and diastereoselective syntheis of 4'-α-substituted carbocyclic
	nucleosides, Tetrahedron: Asymmetry, 1998, 911-914, Vol. 9, Elsevier Science Ltd.
	KILPATRICK, J. MICHAEL, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2'-
	deoxyguanosine in primates, <i>International Immunopharmacology</i> , 2003, 541-548, Vol. 3,
	Elsevier Science B.V.
	KIM, CHOUNG UN et al., Regiospecific and Highly Stereoselective Electrophilic Addition to
	Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against
	HIV, J. Org. Chem., 1991, 2642-2647, Vol. 56, No. 8, American Chemical Society.
	KINSKY, STEPHEN C. et al., Inhibition of cell proliferation by putative metabolites and non-
	degradable analogs of methotrexategamadimyristoylphosphatidylethanolamine, <i>Biochimica</i> et <i>Biphysica Acta</i> , 19878, 211-218, Vol. 917, No. 2., Elsevier Science Publishers B. V.
	KINSKY, STEPHEN C. et al., Effect of liposomes sentitized with methotrexate-γ-
	dimyristoylphosphatidylethanolamine on cells that are resistant to methotrexate, Biochimica et
	Biophysica Acta, 1986, 129-135, Vol. 885, Elsevier Science Publishers B.V.
	KINSKY, STEPHEN C. et al., Circumvention of the methotrexate transport system by
	methotrexate-phosphatidylethanolamine derivatives effect of fatty acid chain length, <i>Biochimica et Biophysica Acta</i> , 1987, 96-103, Vol. 921, Elsevier Science Publishers B.V.
	KO, OK HYUN et al., Efficient synthesis of novel carbocyclic nucleosides via sequential
	Claisen rearrangement and ring-closing metathesis, <i>Tetrahedron Letters</i> , 2002, 6399-6402,
	Vol. 43, Elsevier Science Ltd.
	LEWANDOWICZ, ANDRZEJ et al., Achieving the Ultimate Physiological Goal in Transition
	State Analogue Inhibitors for Purine Nucleoside Phosphorylase, <i>The Journal of Biological Chemistry</i> , 2003, 31465-31468, Vol. 278, No. 34, The American Society for Biochemistry and
	Molecular Biology, Inc.
	MENENDEZ-ARIAS, LUIS et al. Targeting HIV: antiretroviral therapy and development of drug
	resistance, TRENDS in Pharmacological Sciences, 2002, 381-388, Vol. 23, No. 8, Elsevier
	Science Ltd.
	ONO-NITA, SUZANE KIOKO et al., Novel Nucleoside Analogue MCC-478 (LY582563) Is
	Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus, Antimicrobial Agents
	and Chemotherapy, 2002, 2602-2605, Vol. 46, No. 8, American Society for Microbiology.  PANKIEWICZ, KRZYSZTOF W., Novel Mycophenolic Adenine Bis(phosphonate) Analogues
	As Potential Differentiation Agents against Human Leukemia, <i>J. Med. Chem.</i> , 2002 703-712,
	Vol. 45, No. 3, American Chemical Society.
	PARANG, KEYKAVOUS et al., Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-
	Azido-2', 3'-dideoxythymidine (AZT), Current Medicinal Chemistry, 2000, 995-1039, Vol. 7, No.
	10, Bentham Science Publishers Ltd.
	PRASHAD, MAHAVIR et al., An Efficient and Large-Scale Enantioselective Synthesis of
	PNP405: A Purine Nucleoside Phosphorylase Inhibitor, <i>J. Org. Chem.</i> , 2002, 6612-6617, Vol. 67, No. 19, American Chemical Society.
	or, No. 10, American Orientical Occiety.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 5 of 6	01692.315US2	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner	Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source
Initials*	(book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	RAY, ADRIAN S. et al., Role of Purine Nucleoside Phosphorylase in Interactions between 2',
	3'-Dideoxyinosine and Allopurinal, Ganciclovir, or Tenofovir, Antimicrobial Agents and
	Chemotherapy, 2004, 1089-1095, Vol. 48, No. 4, American Society for Microbiology.
	REED, LEFF et al., Antidiabetic PPARy Ligands: An update on Compounds in development,
	Curr. Med. Chem. – Imun., Endoc. & Metab. Agents, 2002, 33-47, Vol. 2, No. 1, Bentham
	Science Publishers Ltd.
	ROBERTS, STANLEY M., Development of the route to the new anti-AIDS drug abacavir: A
	highlight of academic/industry laison, <i>IDrugs</i> , 1998, 896-899, Vol. 1, No. 8, Current Drugs Ltd.  ROSOWSKY, ANDRE <i>et al.</i> , METHOTREXATE ANALOGUES—27, <i>Biochemical</i>
	Pharmacology, 1986, 3327-3333, Vol. 35, No. 19, Pergamon Journals Ltd.
	ROSOWSKY, ANDRE <i>et al.</i> , Methotrexate Analogues, 32, Chain Extension, α-Carboxyl
	Replacement by Sulfonate and Phosphonate: Effect on Enzyme Binding and Cell-Growth
	Inhibition, <i>J. Med. Chem.</i> , 1988, 1326-1331, Vol. 31, No. 7, American Chemical Society.
	SCHULTZ, C., Prodrugs of biologically active phosphate esters, <i>Bioorganic &amp; Medicinal</i>
	Chemistry, 2003, 885-898, Vol. 11, Elsevier Science Ltd., GB.
	SEKIYA, KOUICHI et al., 2-Amino-6-arylthio-9-[2-(phosphonomethoxy) ethyl) purine Bis(2,2,2-
	trifluoroethyl) Esters as Novel HBV-Specific Antiviral Reagents, Journal of Medicinal
	Chemistry, 2002, 3138-3142, Vol. 45, No. 14, American Chemical Society.
	SHI, WUXIAN et al., Plasmodium falciparum Purine Nucleoside Phosphorylase, The Journal of
	Biological Chemistry, 2004, 18103-18106, Vol. 279, No. 18, The American Society of
	Biochemistry and Molecular Biology, Inc.
	SINTCHAK, MICHAEL D. et al., The structure of inosine 5'-monophosphate dehydrogenase
	and the design of novel inhibitors, Immunopharmachology, 2000, 163-184, Vol. 47, Elsevier.
	SRINIVAS, RANGA V. et al., Metabolism and In Vitro Antiretroviral Activities of
	Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates, Antimicrobial Agents
<u> </u>	and Chemotherapy, 1993, 2247-2250, Vol. 37, No. 10, American Society for Microbiology.  STURTZ, GEORGES <i>et al.</i> , Su rune nouvelle approche de pharmacomodulation du
	methotrexate: synthese d'analogues gem-diphosphoniques d'amethopterine et de la N-10
	deaza amethopterine, Medicinal Chemistry, C. R. Acad. Sci. Paris, 1990, Vol. 10, No. 2, 739-
	742, Academie des Sciences.
	STURTZ, GEORGES et al., Analogues phosphonoglutamiques d'amethopterine
	(methotrexate), Eur. J. Med. Chem - Chim. Ther., 1984, 267-273, Vol. 19, No. 3.
	STURTZ, G. et al., Synthesis of gem-bisphosphonic methotrexate conjugates and their
	biological response towards Walker's osteosarcoma, Eur. J. Med. Chem., 1993, 899-903, Vol.
	28, Elsevier.
	STURTZ, G. et al., A study of the delivery-targeting concept applied to antineoplasic drugs
	active on human osteosarcoma, I. Synthesis and biological activity in nude mice carrying
	human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues, Eur J. Med.
	Chem., 1992, 825-833, Vol. 27, No. 8, Elsevier.
	VIELHABER, BERND, Bericht vom 3rd International Workshop on Salvage Therapy for HIV-
	Infection, Deutsche Aids-Hilfe e.V. FaxReport zu HIV und AIDS, 2000, 12-14.  WAEGELL W. et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft
	rejection, Transplantation Proceedings, 2002, 1411-1417, Vol. 34.
L	rejection, transplantation Proceedings, 2002, 1411-1417, Vol. 34.

Substitute for form 1449A/PTO and/or 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Camplete if Known	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 6 of 6	01692.315US2	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	· · · · · · · · · · · · · · · · · · ·		
	WROBLEWSKI, ANDRZEJ et al., Synthesis of (1R,2S)- and (1S,2S)-3-(4-carbamoyl-1,2,3-		
	triazol-1-yl)-1,2-dihydroxypropylphosphonates, Tetrahedron: Asymmetry, 2004, 1457-1464, Vol. 15, Elsevier.		